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ABSTRACT 28 
We previously reported that MORC3, a protein associated with promyelocytic leukemia 29 
nuclear bodies (PML NBs), is a target of HSV-1 ICP0 mediated degradation. Since it is well 30 
known that certain other components of the PML NB complex play an important role during 31 
an intrinsic immune response to HSV-1, and are also degraded or inactivated by ICP0, we 32 
further investigate here the role of MORC3 during HSV-1 infection.  We demonstrate that 33 
MORC3 has antiviral activity during HSV-1 infection and that this antiviral role is 34 
counteracted by ICP0. In addition, MORC3’s antiviral role extends to wild type (wt) HCMV 35 
infection as its plaque forming efficiency increased in MORC3 depleted cells. We found that 36 
MORC3 is recruited to sites associated with HSV-1 genomes after their entry into the nucleus 37 
of an infected cell, and in wt infections this is followed by its association with ICP0 foci prior 38 
to its degradation. The RING finger domain of ICP0 was required for degradation of MORC3 39 
and we confirmed that no other HSV-1 protein is required for the loss of MORC3. We also 40 
found that MORC3 is required for fully efficient recruitment of PML, Sp100, hDaxx and 41 
γH2AX to sites associated with HSV-1 genomes entering the host cell nucleus. This study 42 
further unravels the intricate ways in which HSV-1 has evolved to counteract the host 43 
immune response and reveals a novel function for MORC3 during the host intrinsic immune 44 
response. 45 
 46 
IMPORTANCE 47 
Herpesviruses have devised ways to manipulate the host intrinsic immune response to 48 
promote their own survival and persistence within the human population. One way in which 49 
this is achieved is through degradation or functional inactivation of PML nuclear body (PML 50 
NB) proteins which are recruited to viral genomes in order to repress viral transcription. 51 
Because MORC3 associates with PML NBs in uninfected cells, and is a target for HSV-1 52 
mediated degradation, we investigated the role of MORC3 during HSV-1 infection. We 53 
found that MORC3 is also recruited to viral HSV-1 genomes and importantly it contributes to 54 
the fully efficient recruitment of PML, hDaxx, Sp100 and γH2AX to these sites. Depletion of 55 
MORC3 resulted in an increase in ICP0-null HSV-1 and wt HCMV replication and plaque 56 
formation, and therefore this study reveals that MORC3 is an antiviral factor which plays an 57 
important role during HSV-1 and HCMV infection.  58 
59 
 60 
INTRODUCTION 61 
Herpes simplex virus 1 (HSV-1) is endemic in populations throughout the world and 62 
responsible for a number of clinically important diseases that range from facial and genital 63 
lesions to encephalitis (1, 2). This alpha herpesvirus establishes lifelong persistence within 64 
the host, remaining latent within sensory ganglia after the primary infection is resolved. 65 
Periodically the virus is reactivated from its latent state resulting in recurrent lesions. HSV-1 66 
has the capacity to remain persistent within the host and allow transmission within the 67 
population due to a variety of immune evasion strategies which it encodes.  68 
 Upon initial infection there is activation of an intrinsic immune response involving 69 
constitutively expressed proteins such as the promyelocytic leukaemia (PML) protein and 70 
other components of the PML nuclear body (PML NB) complex (e.g. Sp100 and hDaxx), 71 
which restrict viral gene replication (3-6). Wild-type (wt) HSV-1 overcomes this aspect of 72 
restriction though expression of the viral ubiquitin E3 ligase protein, ICP0, that preferentially 73 
targets specific SUMO (small ubiquitin-like modifier) modified proteins for proteasome-74 
mediated degradation. These include PML and certain other components of the PML NB 75 
complex (7, 8). In addition to these PML NB associated proteins, HSV-1 infection results in 76 
an extensive reduction of high molecular weight SUMO-conjugated proteins at late times of 77 
infection. We recently used SILAC proteomics and mass spectrometry to identify a number 78 
of these SUMO2-modified proteins whose abundance is altered during HSV-1 infection (9). 79 
MORC3 (microrchidia family CW-type zinc-finger 3, also known as NXP-2) was one such 80 
sumoylated protein which we discovered was decrease in abundance by 5.6 fold during HSV-81 
1 infection. We went on to confirm that MORC3 was indeed sumoylated and that both 82 
sumoylated and unmodified forms were degraded during HSV-1 infection in an ICP0-83 
dependent manner (9).  84 
 MORC3 is a nuclear matrix protein whose functional domains are highly conserved 85 
between prokaryotes and eukaryotes (10, 11), however the function of MORC3 has not been 86 
studied in great detail. Interestingly, previous reports showed that MORC3 can associate with 87 
PML NBs (12). The localization of MORC3 to PML NBs is dependent on a SUMO-SIM 88 
(SUMO Interaction Motif) interaction with PML isoform I (PML.I) (13). In addition, 89 
Takahashi and colleagues found that Sp100 and p53 were recruited to PML NBs in a 90 
MORC3- dependent manner, providing some insight into the function of MORC3 within 91 
these complexes. MORC3 was also found to form nuclear body complexes in a PML-92 
independent manner after transient over-expression, with the function of these structures 93 
unknown (13).  94 
 In humans there are five members of the MORC family; MORC1-4 and the divergent 95 
SMCHD1 protein (structural maintenance of chromosome flexible hinge domain containing 96 
1). There are three conserved domains within MORC3; the GHL (gyrase B, Hsp90, and 97 
MutL) ATPase domain (14), a CW-type zinc finger domain (15), and a coiled-coil 98 
dimerization domain (16, 17). The GHL-ATPase domain is thought to be involved in gene 99 
silencing and regulation of chromatin structure in response to DNA damage signals (18-20), 100 
and is required for localization of MORC3 to PML NBs and the recruitment of Sp100 and 101 
p53 to these structures (12). The CW-type zinc finger domain contains a histone H3 binding 102 
motif which binds predominantly methylated lysine 4 of histone H3 (21-23). The function of 103 
the coiled-coil domain within MORC proteins is unknown, although this domain in other 104 
proteins has been suggested to regulate protein-protein and protein-DNA interactions, protein 105 
localization, gene transcription, the DNA damage response and signal transduction (24-43).  106 
 It has been suggested, therefore, that MORC3 is an epigenetic regulator that may play 107 
roles within a wide range of biological functions such as transcription regulation, chromatin 108 
condensation and remodeling, and DNA break repair (44). Members of the MORC family of 109 
proteins have been associated with a number of types of cancers (45-49). However, to date 110 
there is little known about the role that MORC3 may play during a virus infection, although 111 
one recent study reported that MORC3 is required for efficient influenza replication (50). 112 
Until now, MORC3 has not been previously reported to have an antiviral role. Following our 113 
discovery that sumoylated MORC3 is targeted by ICP0 (9), we examined here the function of 114 
MORC3 during infection with HSV-1 and found that it is efficiently recruited to incoming 115 
HSV-1 genomes at early times post infection. We also discovered that during ICP0-null 116 
mutant infection of MORC3 depleted cells the recruitment of Sp100, hDaxx, PML and 117 
γH2AX to incoming viral genomes were less efficient. In addition, we observed that MORC3 118 
colocalized with ICP0 early during infection, prior to its degradation in a RING-finger 119 
dependent manner. Importantly, MORC3 was found to have antiviral activity which is 120 
counteracted in the presence of ICP0, and that MORC3 restricts wt human cytomegalovirus 121 
(HCMV) plaque formation efficiency, suggesting that MORC3 has an antiviral role that 122 
extends beyond HSV-1. 123 
 124 
 125 
MATERIALS AND METHODS 126 
Viruses and cells. HSV-1 wild type (wt) strain 17+ was used, from which the ICP0 null 127 
mutant dl1403 was derived (51). Wild type HSV-1, in1863, and the derivative 128 
dl1403/CMVlacZ, both contain the lacZ gene under the control of the HCMV 129 
promoter/enhancer inserted into the tk gene and were gifts from Chris Preston. HSV-1 dl0Y4 130 
expresses EYFP-linked ICP4 and was derived from dl1403 (52). Viruses were propagated in 131 
Baby Hamster kidney (BHK) cells grown in Glasgow modified Eagles' medium (Gibco Life 132 
Technologies) supplemented with 10% newborn calf serum (Gibco Life Technologies) and 133 
10% tryptose phosphate broth (Gibco Life Technologies). Virus titres were determined by 134 
titration on U2OS cells in the presence of 1% human serum (MP Biomedicals). Viral plaques 135 
were visualized using Geimsa stain (VWR). Human foreskin diploid human fibroblasts (HFs, 136 
a gift from Thomas Stamminger), telomerase-immortalized HFs (HFTs, a gift from Chris 137 
Boutell), HEK-293T cells and U2OS cells were all grown in Dulbecco's modified Eagles' 138 
medium (Gibco Life Technologies) supplemented with 10% fetal bovine serum (FBS) (Gibco 139 
Life Technologies), 100 units/ml penicillin and 0.1 mg/ml streptomycin (Gibco Life 140 
Technologies). HepaRG cells (53), were grown in William's medium E (Gibco Life 141 
Technologies) supplemented with 10% FBS, 2 mM glutamine (Gibco Life Technologies), 5 142 
μg/ml insulin (Sigma-Aldrich), and 500 nM hydrocortisone (Sigma-Aldrich). HepaRG cells 143 
that can be induced to express ICP0 (HA-cICP0), or ICP0 mutants (HA-FXE, HA-mSLS4, 144 
HA-mSLS457, HA-E52X) in the presence of doxycycline (0.1 µg/ml) (Clontech) were 145 
described previously (7, 54). Lentivirus transduced cells were maintained with the 146 
appropriate antibiotic selection. 147 
 Plasmids and lentiviral vectors. Lentivirus vectors expressing anti-MORC3 shRNA 148 
(shMORC3) were obtained from Sigma-Aldrich (shMORC3-1335:CCGGGCTTAATACGT 149 
GTCGGTCATACTCGAGTATGACCG ACACGTATTAAGCTTTTT), (shMORC3-1337: 150 
CCGGGCCAATTACAAGAACTGAGAACTCGAGTTCTCAGTTCTTGTAATTGGCTTT151 
TT), (shMORC3-1339: CCGGGTGAGGTTGAATTGCTGGAAACTCGAGTTTCCAGCA 152 
ATTCAACCTCACTTTTT). Lentivirus transduction of cells was as described previously 153 
(55). Briefly, pLKO plasmids expressing the gene of interest were cotransfected along with 154 
pVSV-G and pCMV.DR.8.91 (a gift from Didier Trono) into HEK-293T cells. Lentivirus 155 
supernatants were collected and HFT and HepaRG cells transduced. Selection during routine 156 
culture used puromycin at 500 ng/ml, which were omitted from cells seeded for and during 157 
experimentation. HA-cICP0 cells and their derivatives were maintained in media containing 158 
G418 (500 µg/ml) and puromycin. 159 
Virus plaque assays. The relative plaque forming efficiencies of wt and ICP0 null 160 
mutant HSV-1 were assessed as described (56), with HFT-shMORC3 cells seeded for plaque 161 
assays into 24-well dishes at 1 x 105 cells per well, and infected the following day with 162 
appropriate sequential 3-fold dilutions of dl1403/CMVlacZ or wt in1863. After virus 163 
adsorption, the cells were overlayed with medium containing 1% human serum. The cells 164 
were then stained for β-galactosidase positive plaques 24 h later. Relative plaque formation 165 
efficiencies are expressed as fold changes in plaque numbers at a given dilution compared to 166 
the control. This approach gives a more robust and reliable comparison compared to apparent 167 
titres averaged over a range of dilutions because the plaque forming efficiency of ICP0 null 168 
mutant HSV-1 varies in a non-linear manner with respect to dilution. For assay of HCMV 169 
plaque formation, HFT-shMORC3 and control cells were seeded into 24-well dishes and 170 
infected with HCMV at appropriate multiplicities the following day. At 3 h after virus 171 
adsorption, the virus inoculum was removed and replaced with fresh medium. Plaques were 172 
stained at 10 days after infection by immunological detection of UL44 (ab6502, Abcam). The 173 
cells were fixed with formaldehyde and treated with NP40 as for immunofluorescence 174 
staining, then washed twice with phosphate-buffered saline (PBS) containing 0.1% Tween-20 175 
(PBST). The cells were treated with PBST containing 5% dried milk for 30 minutes and then 176 
incubated for 2 h at room temperature with anti-UL44 monoclonal antibody.  The cells were 177 
then washed three times with PBST before being incubated with horse radish peroxidase 178 
(HRP) conjugated goat anti-mouse secondary antibody for 1 h. The cells were washed with 179 
PBST three times and incubated with 0.2 ml True Blue solution (50-7802, Insight 180 
Biotechnology) for 10 minutes. 181 
 Western blot analysis. Cells were seeded into 24-well dishes at 1 x 105 cells per 182 
well. After the relevant experimental manipulations, the cells were washed twice with PBS 183 
before harvesting in sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) 184 
loading buffer. Proteins were resolved on 7.5% SDS-PAGE and then transferred to 185 
nitrocellulose membranes by western blotting. The following primary antibodies were used: 186 
anti-actin mAb (AC-40) (Sigma-Aldrich) (1:10,000), anti-PML mAb (5E10) (57) (1:100), 187 
anti-tubulin mAb (T4026) (Sigma-Aldrich) (1:5000), anti-ICP0 mAb (11060) (58) (1:1000), 188 
anti-ICP4 mAb (58S) (59) (1:1000), anti-UL42 mAb (Z1F11) (60) (1:1000), anti-Sp100 rAb 189 
(SpGH) (61) (1:2000), anti-MORC3 rAb (NBP1-83036) (Novus Biologicals) (1:300), anti-190 
RanGAP1 mAb (33-0800) (Invitrogen) (1:1000). Secondary antibodies included: anti-mouse-191 
HRP (A4416) (Sigma-Aldrich) (1:1500), anti-Rabbit-HRP (A4914) (Sigma-Aldrich) 192 
(1:20,000). 193 
Immunofluorescence and confocal microscopy. Cells were seeded onto 13 mm 194 
glass coverslips within 24-well plates at 1 x 105 cells per well, fixed and prepared for 195 
immunofluorescence as described (62). Antibodies used were: anti-PML mAb (5E10) (57) 196 
(1:20), anti-Sp100 rat serum (Sp26) (63) (1:2000), anti-MORC3 rAb (NBP1-83036) (Novus 197 
Biologicals) (1:400), anti-ICP0 mAb (11060) (58) (1:1000), anti-hDaxx mAb (MCA2143) 198 
(AbD Serotech) (1:1000), anti-Phospho-H2AX (Ser139) rAb (clone JBW301-Upstate) 199 
(1:1000) and nuclei were stained with DAPI (Sigma-Aldrich). The secondary antibodies used 200 
were Alexa 555 conjugated goat anti-mouse IgG (Life Technologies) (1:5000), Alexa 633 201 
conjugated goat anti-rabbit IgG (Life Technologies) (1:1000), Alexa 488 conjugated goat 202 
anti-mouse IgG (Life Technologies) (1:1000), Alexa 488 conjugated goat anti-rat IgG (Life 203 
Technologies) (1:1000) and Alexa 555 conjugated goat anti-rat IgG (Life Technologies) 204 
(1:5000). Immunofluorescence assays were done in replicate and complete coverslips were 205 
examined in detail using a Zeiss LSM 710 confocal microscope, with 488 nm, 561 nm and 206 
633 nm laser lines, scanning each channel separately under image capture conditions that 207 
eliminated channel overlap. 208 
 209 
RESULTS 210 
MORC3 colocalizes with ICP0 prior to its degradation. MORC3 can be detected within 211 
PML NBs and in one reported instance was found to be required for recruitment of Sp100 212 
into these nuclear complexes (12, 13). Our study also observed MORC3 in association with 213 
PML NBs, although following examination of a large number of cells we noted that not every 214 
PML NB complex had detectable MORC3 (Fig. 1, see also Figs. 4 and 5 below). This 215 
difference may be due to differences in cell types analyzed and methods used, or a limit of 216 
antibody detection efficiency. At the early stages of HSV-1 infection, ICP0 colocalizes with 217 
PML NB protein components such as PML and Sp100 prior to their degradation (8, 64-67). 218 
Since we have previously shown that both sumoylated and unmodified MORC3 is degraded 219 
during wt HSV-1 infection (9), we investigated whether MORC3 also colocalizes with ICP0 220 
prior to its degradation. Human diploid fibroblasts (HFs) were infected for 1 h with wt HSV-221 
1 at multiplicity of infection (MOI) of 2 plaque forming units (pfu) per cell. The localization 222 
of ICP0 and MORC3 were then visualized using immunofluorescence staining and confocal 223 
microscopy, with mock infected cells included as a control (Fig. 1). Complete coverslips 224 
were examined of which 21 and 38 cells were imaged at 1 and 2 h p.i, respectively. We found 225 
that by 1 h after wt HSV-1 infection MORC3 colocalizes with ICP0 (cell indicated with 226 
arrow), prior to loss of the MORC3 signal in cells where ICP0 expression is more intense. By 227 
2 h post infection all cells expressing ICP0 contained no detectable MORC3 protein, with 228 
MORC3 only found in uninfected cells within this population. Some colocalization of 229 
MORC3 with an ICP0 RING-finger mutant was also observed (data not shown), suggesting 230 
this association is independent of the RING finger domain of ICP0. Therefore, MORC3 231 
colocalizes with ICP0 very early during infection prior to its degradation. 232 
 MORC3 is degraded in an ICP0 dependent manner during HSV-1 infection. Our 233 
previous study found that ICP0 expressed on its own  is sufficient to cause a reduction in 234 
MORC3 protein abundance (9). However, it remains possible that other HSV-1 proteins 235 
display similar activity. Therefore, to confirm that no other HSV-1 proteins are capable of 236 
causing the degradation of MORC3 we infected telomerase-immortalized HFs, with ICP0-237 
null mutant HSV-1(MOI 20) over a time course infection, with wt HSV-1 (MOI 2) included 238 
as a control. The different multiplicities of wt and mutant were used to enable similar rates of 239 
infection progression. Western blot analysis indeed confirmed that wt but not ICP0-null 240 
mutant HSV-1 infection results in a loss of MORC3 (Fig. 2). Therefore, we have shown 241 
through expression of ICP0 alone (9), and infection with an ICP0-null HSV-1, that ICP0 is 242 
the only HSV-1 protein required for the observed reduction in MORC3. 243 
 The RING finger domain of ICP0 is required for MORC3 degradation. The 244 
region of ICP0 required for the degradation of MORC3 was assessed by utilizing cells that 245 
can be induced to express wt or mutant forms of ICP0 (54, 68). In this study we utilized 246 
mutants of ICP0 that lack the RING finger domain, one or more of the motifs resembling 247 
SIMs termed SIM-like sequences (SLS1-7) and a C-terminal deletion (Fig. 3A). Each region 248 
has individually been shown to be involved in the efficiency of degradation of selected 249 
proteins. The RING finger domain functions as a ubiquitin ligase which is required for 250 
degradation of many proteins including unsumoylated PML.I, while the SLS motifs are likely 251 
to influence target specificity of the RING finger activity by binding to SUMO moieties 252 
which are conjugated to sumoylated proteins. We have found that the SLS4 motif is involved 253 
in targeting specific sumoylated proteins including NACC1, ZBTB10, ZBTB4, ETV6 and 254 
specific PML isoforms (7, 9, 69) and data not shown). However the SLS4 motif was not 255 
required for degradation of other sumoylated proteins such as MBD1, BEND3, ZBTB12, 256 
NACC2 or ARID3a (9) and data not shown), demonstrating there is specificity in the SLS4-257 
targeted group of proteins. A combination of mutations within these SLS motifs (mSLS457) 258 
diminishes ICP0 function and reduces the rate at which it causes the extensive reduction in 259 
high molecular weight SUMO conjugates (7). There are also motifs within the C-terminal 260 
region of ICP0 that have been implicated in binding to other proteins (70-72). To identify the 261 
regions of ICP0 that are involved in the degradation of MORC3, cells were induced to 262 
express either full length ICP0, ICP0 RING finger deletion (FXE), ICP0 C-terminal deletion 263 
(E52X), ICP0 with a mutation in the SLS4 motif (mSLS4) or a combination of mutations in 264 
SLS4, 5 and 7 (mSLS457). Western blot analysis of these cell lysates prepared with or 265 
without ICP0 induction included PML as a control (Fig. 3B). As expected from previous 266 
results, expression of wt ICP0 and mutants E52X and mSLS4 caused substantial degradation 267 
of PML (7). The reduction in the PML band intensity in the RING finger mutant FXE sample 268 
in this particular gel was not reproducible and was not observed in a number of previous 269 
published reports (for example (54)) and therefore we regard this as spurious. Degradation of 270 
sumoylated PML isoforms is evident in the cells expressing ICP0 mutant SLS457, which is 271 
consistent with previous observations (7) The role of the SLS motifs in degrading 272 
endogenous PML is complicated, because they are not absolutely required for degrading 273 
PML.I or its sumoylated forms (although their degradation by mSLS457 is slightly less 274 
efficient than by wt), while SLS4 is required for degradation of all forms of PML.II when 275 
expressed in isolation (68, 73). Therefore a major component of the PML band remaining in 276 
the right-most lane of Fig. 3 is likely to be unsumoylated PML.II. MORC3 was found to be 277 
degraded by all mutants analyzed except FXE, indicating the RING finger domain of ICP0, 278 
and not the C-terminal region or the SLS motifs, is required for this effect. In this respect the 279 
degradation of MORC3 resembles that of PML.I, which is RING finger dependent but SLS 280 
motif independent (73). In this latter instance, the degradation of PML.I could be attributed to 281 
a direct interaction between ICP0 and PML.I (73). Whether this is the case with MORC3 282 
remains to be determined, although this would not be straightforward to investigate because 283 
of the rapidity of MORC3 degradation in the presence of ICP0. 284 
 MORC3 is recruited to HSV-1 genomes. Sp100, PML and other PML NB protein 285 
components are recruited to HSV-1 genomes entering the nucleus of an infected cell in a 286 
process that contributes to the repression of viral gene transcription (54, 55, 62, 74-76). This 287 
repression is counteracted by ICP0 mediated degradation of selected PML NB protein 288 
components (reviewed in (3)). The assay for the recruitment of PML NB proteins to HSV-1 289 
genomes involves immunofluorescence staining of viral plaques on an infected monolayer of 290 
cells with an ICP4 antibody, which acts as a marker for HSV-1 genomes through its efficient 291 
association with the viral DNA. Cells at the edges of developing plaques receive a high 292 
number of viral genomes, visible as an arc-like pattern just inside the nucleus. This 293 
asymmetric pattern allows unambiguous visualization of recruitment of cellular proteins to 294 
sites associated with the viral genome foci. This recruitment is much more readily seen in 295 
ICP0 null mutant HSV-1 infections as ICP0 very rapidly counteracts the recruitment process 296 
(62). Since MORC3 was reported to colocalize with PML NB proteins, PML and Sp100 (12, 297 
13), and has also been suggested as a DNA binding protein and transcriptional repressor (77), 298 
we set out to determine if MORC3 is also recruited to HSV-1 genomes. Due to the rapid 299 
degradation of MORC3 following infection we utilized an ICP0-null mutant HSV-1 300 
expressing an EYFP tagged ICP4 (dl0Y4) in order to visualize recruitment more clearly. We 301 
infected HFs with dl0Y4 for 24 h at a low MOI and imaged 10 representative cells at the 302 
periphery of developing plaques which exhibited ICP4 foci around the nuclear periphery. 303 
Immunofluorescence staining for Sp100 was included as a positive control for recruitment 304 
and uninfected (mock) cells as a negative control, which confirmed previous reports of 305 
MORC3 and Sp100 colocalization (12). As expected, we found close association of Sp100 306 
with EYFP-ICP4 foci around the internal periphery of the nucleus of all newly infected cells, 307 
indicative of Sp100 recruitment to HSV-1 genomes entering the nucleus (a typical example is 308 
shown in Fig. 4). MORC3 was also in these recruited foci within these cells, demonstrating 309 
that MORC3 is indeed recruited to HSV-1 genomes during the initial stages of infection (Fig. 310 
4).  311 
 MORC3 influences the recruitment of PML NB components to HSV-1 genomes. 312 
The recruitment of the PML NB complex proteins (for example PML, Sp100 and hDaxx) to 313 
HSV-1 genomes entering the nucleus of an infected cell occurs independently of each other 314 
(55, 74, 76, 78, 79). The precise mechanism responsible for the recruitment of these factors 315 
remains unknown, although it has been established that in each of these three cases the 316 
presence of a SIM is essential (75). Since MORC3 was recruited to HSV-1 genomes and 317 
directly interacts with PML.I, and in one situation is required for Sp100 localizing to PML 318 
NBs (12, 13), we investigated whether MORC3 influences the recruitment of these other 319 
factors to HSV-1 genomes. In addition, another MORC family protein, MORC2, has been 320 
reported to induce phosphorylation of H2AX and the subsequent formation of γH2AX foci 321 
and chromatin relaxation (20), which are steps in the pathway to double-strand (ds)-break 322 
repair (80). Because it has been established that γH2AX forms regions surrounding 323 
replicating HSV-1 genomes in a ds-break repair response (81-83), we therefore included 324 
γH2AX in our panel of proteins to investigate whether their recruitment was influenced by 325 
MORC3.  326 
 To investigate this hypothesis we established HFT and HepaRG cell lines depleted of 327 
MORC3 using independent shRNAs, namely shMORC3-1335 and -1339, with the extent of 328 
depletion assessed by western blot analysis (Figures 5A). Depletion of MORC3 in HFT- and 329 
HA-shMORC3-1339 cells was then confirmed by confocal microscopy, co-staining with 330 
PML (Fig. 5B and C, left panels). Since a previous study found depletion of MORC3 from 331 
HeLa cells resulted in dispersal of Sp100 (12), we also examined the effect of MORC3 332 
depletion on Sp100 localizing with PML in our cells (Fig. 5B and C, right panels). 333 
Surprisingly, in the HFTs examined here, Sp100 remained within PML NBs of uninfected 334 
cells when MORC3 was depleted. The difference we observe here may be due to differences 335 
in the cell types analyzed, the level of depletion of MORC3 or the antibodies utilized. The 336 
great majority of mock infected HFT-shMORC3 cells, of which 95 were imaged, had no 337 
detectable MORC3 expression and showed Sp100, PML, hDaxx and γH2AX with the typical 338 
nuclear dot formation distributed throughout the nucleus (data not shown).Uninfected HA-339 
shMORC3-1339 cells also displayed Sp100 within PML NBs when MORC3 was more 340 
efficiently depleted (Fig. 5C). 341 
 Whether MORC3 was required for recruitment of PML, Sp100, hDaxx or γH2AX to 342 
sites associated with HSV-1 genomes was assessed by infecting HFT-shMORC3-1339 cells 343 
with dl0Y4 (as explained above). Cells were then stained for either PML (FEig. 6A), Sp100, 344 
hDaxx, or γH2AX (data not shown) as well as MORC3 to confirm MORC3 depletion in these 345 
particular individual cells. Foci of EYFP-ICP4 indicate the localization of HSV-1 genomes 346 
and the nucleus was stained with DAPI. HFT-shNeg cells were included as a control in which 347 
MORC3 could be co-stained with either Sp100, PML, hDaxx or γH2AX and tested for 348 
recruitment to HSV-1 genomes.  349 
 Cells that displayed EYFP-ICP4 around the internal nuclear periphery were 350 
characterized as newly infected cells with HSV-1 genomes entering the nucleus upon 351 
infection (Figure 6A, ICP4+/PML+). We could also identify cells very early following 352 
infection due to the rapid recruitment of PML NB proteins to HSV-1 genomes prior to 353 
detectable levels of ICP4 expression; such cells have asymmetric PML foci of a type that are 354 
never seen in uninfected cells (Figure 6A, ICP4-/PML+). Thus a study that was blinded from 355 
the point of view of the observer was performed in which infected, or presumed infected cells 356 
surrounding a plaque were identified and divided into the following categories: 1) Those 357 
containing foci of both ICP4 and Sp100, PML, γH2AX or hDaxx in close association at the 358 
nuclear periphery of a cell (referred to as ICP4+/X+); 2) Those containing foci of Sp100, 359 
PML, γH2AX or hDaxx at the nuclear periphery of a cell in the pattern typical of an infected 360 
cell, but prior to detectable expression of ICP4 (referred to as ICP4-/X+); or 3) Those 361 
containing ICP4 foci only at the nuclear periphery of a cell, without accompanying foci of the 362 
cellular protein in question (referred to as ICP4+/X-) (Fig. 6A). Our analysis showed that in 363 
the absence of MORC3 the recruitment of PML was less efficient with 48% of 69 counted 364 
cells described as ICP4+/PML- (Fig. 6B). Only 1% of counted cells were assigned as ICP4-365 
/PML+, with the remaining 51% of cells  ICP4+/PML+, although visually the abundance of 366 
PML foci at the nuclear periphery appeared to be of a lesser degree than the equivalent shNeg 367 
control. Of note, some of these shMORC3 cells exhibiting PML recruitment also had low 368 
levels of MORC3 remaining and therefore the percentage of cells which are defective for 369 
PML recruitment may be higher than described here. Interestingly MORC3 depleted cells 370 
that had no PML recruitment to ICP4 foci also no longer contained PML as punctate PML 371 
NB structures, suggesting that these structures are less stable in the absence of MORC3 in 372 
infected cells, even if ICP0 is not expressed. The corresponding data for the control HFT-373 
shNeg cells indicated 60% of 40 counted cells were ICP4+/PML+ and 35%  ICP4-/PML+, 374 
indicating that in the presence of MORC3, PML can be recruited very early following 375 
infection, prior to detectable ICP4 expression. Only 5% of counted cells were described as  376 
ICP4+/PML-. We also investigated the reciprocal effect and found that recruitment of 377 
MORC3 was unaffected by depletion of PML (data not shown). 378 
 Sp100 recruitment to sites of incoming HSV-1 genomes was also assessed in these 379 
MORC3 depleted cells in a similar manner (Fig. 6B and data not shown). We found that in 380 
the absence of MORC3, Sp100 is recruited more slowly to viral genomes compared to 381 
MORC3 expressing cells. For example, 54% of the 68 counted control HFT-shNeg cells were  382 
ICP4+/Sp100+ and 46% ICP4-/Sp100+. Unlike with PML, there were no cells that had ICP4 383 
around the periphery of the nucleus that did not have Sp100 recruited to the same site. 384 
However, when MORC3 was depleted only 4% of the 104 counted cells were observed as 385 
ICP4-/Sp100+, while 3% of counted cells were ICP4+/Sp100-. The remaining 93% of 386 
counted cells were designated ICP4+/Sp100+. Thus the rate of recruitment of Sp100 is 387 
decreased in the MORC3 depleted cells. A similar phenotype to Sp100 was seen with γH2AX 388 
and hDaxx (Fig. 6B and data not shown), with 47% of the 43 counted HFT-shNeg cells 389 
displaying ICP4 and γH2AX foci associated at the nuclear periphery (ICP4+/γH2AX+) and 390 
53% with rapid recruitment of γH2AX to the nuclear periphery prior to ICP4 expression 391 
(ICP4-/γH2AX+). In contrast, MORC3 depleted cells displayed 87% of 52 counted cells as 392 
ICP4+/γH2AX+, with only the remaining 13% as ICP4-/γH2AX+. Similarly, for hDaxx 66% 393 
of 71 counted shNeg cells were described as ICP4+/hDaxx+, 32% as  ICP4-/hDaxx+ and the 394 
remaining 1% as ICP4+/hDaxx+. There was evidence of hDaxx recruitment to viral genomes 395 
(ICP4+/hDaxx+) in 82% of 71 counted MORC3 depleted cells, while only 3% of counted 396 
cells were described as- ICP4-/hDaxx+ and 15% as ICP4+/hDaxx-. Taken together, these 397 
results suggest that MORC3 plays a role in the speed or efficiency of recruitment of these 398 
PML NB proteins to incoming HSV-1 genomes.  399 
Since PML is required for the formation of PML NBs (84, 85), and was observed as 400 
diffuse throughout the nucleus in many of these HFT-shMORC3-1339 dl0Y4 infected cells 401 
(Fig 6A and B), it was perhaps surprising to observe some Sp100 remaining as nuclear dots 402 
in unrecruited foci. To further assess this observation mock or dl0Y4 infected HFT-403 
shMORC3-1339 cells were dual stained with Sp100 and PML (Fig. 6C). Our analysis 404 
confirmed that when PML is nuclear diffuse, Sp100 remains as nuclear dots in both ICP4 405 
associated and unassociated foci. We also observed that in some HFTshMORC3 cells PML 406 
staining was apparently less intense than in HFT-shNeg controls, which might be explained 407 
by a greater component of diffuse PML distribution. 408 
MORC3 has antiviral activity during HSV-1 and HCMV infection. In previous 409 
studies, we have noted a correlation between the recruitment of PML NB components and 410 
their role in the restriction of virus gene replication (54, 55, 62, 75, 76) (62, 75, 79, 86), with 411 
their functions in this regard counteracted by ICP0 (reviewed in (3)). Since we discovered 412 
that MORC3 is recruited to HSV-1 genomes we wanted to determine if MORC3 also has an 413 
antiviral role during HSV-1 infection. For these experiments, both HFT and HepaRG (HA) 414 
cells that were depleted of MORC3 using shRNAs shMORC3-1335 and -1339 were assessed 415 
(Fig. 5A). Viral plaque assays were then performed to compare the plaque formation 416 
efficiencies of wt and ICP0-null HSV-1 in these cells (Fig. 7A). Cells expressing a control 417 
shRNA (shNeg) were included to normalize plaque numbers. As expected, because of the 418 
rapid degradation of MORC3 by ICP0, wt HSV-1 exhibited no change in plaque formation 419 
efficiency within both HFT- and HA-shMORC3-1335 and -1339 cells when compared to the 420 
shNeg controls (Fig. 7A). However, ICP0-null HSV-1 infection of MORC3 depleted HFT 421 
and HA cells resulted in a marked increase in plaque formation efficiency compared to the 422 
respective shNeg controls, suggesting that, like several other components of PML NBs, 423 
MORC3 has antiviral activity which is counteracted by ICP0. These increases in plaque 424 
formation efficiency are at least as marked, even in the most conservative estimation, as the 425 
corresponding increases previously seen in cells depleted individually of PML, Sp100 or 426 
hDaxx (55, 74, 76). 427 
 An increase in plaque formation efficiency would result in increased infectivity of the 428 
ICP0-null HSV-1. We therefore confirmed this effect using western blot analysis to detect 429 
viral proteins ICP4, UL42 and ICP0 (control for ICP0-null HSV-1). HFT-shMORC3-1339 430 
cells were infected with ICP0-null HSV-1 (dl1403, labeled ΔICP0) at MOI 2 with samples 431 
collected over a time course infection. ICP4 and UL42 were expressed at greater levels in the 432 
shMORC3 cells compared to the shNeg control, confirming MORC3 depleted cells are more 433 
readily infected (Fig. 7B). 434 
 HCMV is a beta herpesvirus which is also restricted by the same set of PML NB 435 
components as HSV-1, with repression mediated through hDaxx being counteracted by pp71, 436 
and through PML being nullified by IE1 (87-93). Therefore we analyzed these MORC3 437 
depleted HFT cells for their ability to restrict HCMV infection using the same controls as 438 
listed above (Fig. 7C). The plaque forming efficiency of wt HCMV within HFT-shMORC3 439 
cells was also increased when compared to HFT-shNeg cells, illustrating that MORC3 has 440 
antiviral activity towards DNA viruses in addition to HSV-1. The increase in wt HCMV 441 
plaque formation in MORC3 depleted cells observed here is reminiscent of that seen in cells 442 
depleted of PML or Sp100, indicating that even wt HCMV is sensitive to PML NB 443 
component mediated restriction (as described in the studies cited above).  444 
 445 
DISCUSSION 446 
Here we report an antiviral function for the nuclear matrix protein, MORC3. Our previous 447 
study identified sumoylated MORC3 as a degradation target of the HSV-1 E3 ubiquitin ligase 448 
protein, ICP0 (9), which led us to further investigate the function of MORC3 during HSV-1 449 
infection. Until now the role of MORC3 during virus infections was relatively unknown, 450 
although one other report suggested that MORC3 was required for efficient Influenza A virus 451 
(IAV) infection (50). MORC3 is a sumoylated nuclear matrix protein with RNA and DNA 452 
binding activities (13, 17), which associates with PML NBs. This association is through a 453 
SUMO-SIM interaction with PML.I, which requires a functional ATPase domain within 454 
MORC3 (12, 13). In our analysis of HFT cells, we found that MORC3 was detectable in only 455 
a subset of PML NBs, whereas others reported that in HeLa and Saos-2 cells MORC3 was 456 
colocalized to majority of PML nuclear foci. This difference in detail may be due to cell type 457 
or efficiency of antibody detection, and indeed Ver et al found no significant colocalization 458 
of MORC3 with PML in A549 cells (50). One reported role of MORC3 in PML NBs is to 459 
recruit Sp100 and p53 into these complexes (12), although in the HF-derived cells used here 460 
the former function was not evident. The discrepancy may be due to differences in cell types 461 
examined or the efficiency of MORC3 depletion.  462 
Upon infection with HSV-1 there is activation of an intrinsic immune response 463 
including recruitment of protein components of the PML NB complex, including PML, 464 
Sp100 and hDaxx, independently to sites associated with HSV-1 genomes entering the 465 
infected cell nucleus. In the absence of ICP0, this recruitment contributes to cell-mediated 466 
repression of viral gene replication (54, 55, 62, 74, 76, 94). The DNA repair protein γH2AX 467 
also accumulates in regions surrounding the viral genomes (82, 83). The repression mediated 468 
through the recruitment of PML NB components is counteracted by the expression of ICP0 469 
which preferentially degrades sumoylated forms of these proteins, and causes dispersion of 470 
others (7, 8, 64-67). The association of MORC3 with PML NBs in uninfected cells led us to 471 
investigate the recruitment of MORC3 to HSV-1 genomes during the initial stages of 472 
infection, which led to the finding that MORC3 becomes associated with foci of ICP4 in a 473 
similar manner to the well characterized behavior of PML NB components. This provoked 474 
some intriguing questions as to the role of MORC3 during an intrinsic immune response to 475 
HSV-1 infection. We found that PML recruitment was noticeably affected in MORC3 476 
depleted cells, and that Sp100, γH2AX and hDaxx were also recruited less efficiently, 477 
although this defect was not as marked as that of PML. In control cells, there appears to be a 478 
temporal transfer of PML protein from PML NBs to ICP4-associated foci, such that foci of 479 
both types can frequently be observed in the infected cells. However, in a large number of 480 
MORC3 depleted ICP0-null infected cells the PML signal becomes disperse with neither 481 
PML NB-like nor recruited foci. This observation is very intriguing since we still see Sp100 482 
in nuclear foci despite the fact that PML is required for the formation of PML NB complexes 483 
(84, 85). Since these PML NB complexes are dynamic, the lack of detectable punctate 484 
nuclear PML foci in these cells may be due to a change in the equilibrium of PML shuttling 485 
in and out of these structures in a manner that is in some way influenced by MORC3.  486 
Our HSV-1 viral plaque assays in MORC3 depleted cells indicated that MORC3 has 487 
antiviral functions that are counteracted in the presence of ICP0, thus providing the first 488 
report of evidence for an antiviral role for MORC3. To enhance the repertoire of viruses 489 
investigated for the role of MORC3 we also assessed the replication efficiency of the beta-490 
herpesvirus, human cytomegalovirus (HCMV). Like HSV-1, HCMV also counteracts the 491 
PML NB mediated repression of its viral gene transcription (87-93, 95). Infection of our 492 
MORC3 depleted cells with wt HCMV resulted in an increase in plaque formation efficiency 493 
when compared to the control cells. Therefore MORC3 has antiviral activity towards DNA 494 
viruses in addition to HSV-1. It would be of interest to examine other herpesviruses in the 495 
future to determine if this response is general to all herpesviruses.  496 
In summary, we report that MORC3 has an antiviral role during HSV-1 and HCMV 497 
infection. The antiviral effect of MORC3 during HSV-1 infection was counteracted by the 498 
viral ubiquitin ligase protein, ICP0, and we identified that depletion of MORC3 reduces the 499 
efficiency of recruitment of PML NB component proteins to HSV-1 genomes. Because the 500 
recruitment of these PML NB proteins plays an important role during the intrinsic immune 501 
response to HSV-1, this role of MORC3 may underlie why restriction of ICP0-null HSV-1 is 502 
reduced in its absence. It is notable that our interest in MORC3 came through a general 503 
screen of changes in the SUMO2 proteome during HSV-1 infection which eventually and 504 
independently led to connections with PML NB mediated restriction, thus underlining the 505 
biological relevance of virus-PML NB interactions. This study has provided further insight to 506 
the understanding of the intrinsic immune response to HSV-1 and opens a new avenue of 507 
research into MORC3 beyond herpesviruses. 508 
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FIGURE LEGENDS 522 
 523 
Fig. 1:  MORC3 associates with Sp100 in PML NBs and ICP0 early during wt HSV-1 524 
infection and is subsequently degraded. HFs were either mock infected or infected with wt 525 
HSV-1 (MOI 2), fixed and permeabilized at 1 or 2 h post infection. Cells were analyzed for 526 
association of MORC3 (Novus Biologicals) (red) with Sp100 (top row, showing 527 
concentrations of MORC3 associated with Sp100 in a variable manner; see also Fig. 4), and 528 
with ICP0 (11060) (green) in infected cells using confocal microscopy. The blue signal in the 529 
merged channel is DAPI. The arrow indicates a cell with ICP0 in association with MORC3. 530 
The MORC3 signal diminishes as infection progresses. 531 
 532 
Fig. 2: MORC3 is degraded in an ICP0 dependent manner. HFT cells were infected at 533 
MOI 20 with an ICP0 null HSV-1 (ΔICP0) and lyzed at 3, 6, and 9 h p.i. for western blot 534 
analysis. Analysis of PML abundance and wt HSV-1 infected (MOI 2) lysates prepared in 535 
parallel were included as positive controls for degradation. Membranes were probed with 536 
anti-MORC3 (Novus Biologicals) and anti-PML (5E10) antibodies, with anti-tubulin (Sigma-537 
Aldrich) used as a loading control. Viral proteins ICP4 and UL42 were included to show 538 
equivalent infection between wt and ΔICP0 HSV-1. 539 
 540 
Fig. 3: RING finger domain of ICP0 is required for MORC3 degradation. (A) Schematic 541 
diagram of ICP0 displaying internal domains and SIM-like sequences (SLS) as well as 542 
regions of mutations/deletions of the RING finger (FXE) and C-terminal (E52X) domains. 543 
(B) HA-TetR (control) and HA-cICP0, -cICP0 FXE (Δ149-160), -cICP0 E52X (Δ594-775), -544 
cICP0 mSLS4, and -cICP0 mSLS457 cells with the ability to express wt and mutant forms of 545 
ICP0 were treated with doxycycline (Dox) (+) or left untreated (-) then analyzed by western 546 
blot. Membranes were probed with anti-MORC3 (Novus Biologicals), -ICP0 (11060), and -547 
PML (5E10) antibodies, with anti-tubulin (Sigma-Aldrich) included as a loading control. 548 
 549 
Fig. 4: MORC3 is recruited to HSV-1 genomes during the initial stage of infection. HFs 550 
were infected at low MOI with dl0Y4 for 24 h, fixed, permeablized and probed with anti-551 
MORC3 antibody (Novus Biologicals) (purple). Anti-Sp100 (Sp26) (red) was included as a 552 
positive control for recruitment to viral genomes, with nuclei stained with DAPI (blue). 553 
Recruitment to ICP4 was visualized by confocal microscopy (right-hand column), compared 554 
to a typical uninfected cell (left-hand column). 555 
 556 
Fig. 5: Characterization of MORC3 depleted cells. (A) Generation of MORC3 depleted 557 
HFT (HFT-shMORC3-1335 and -1339 cells) and HepaRG cells (HA-shMORC3-1335, -1337 558 
and -1339 cells) using shRNAs expressed from lentiviral vectors. Total protein lysates were 559 
analyzed by western blot to determine level of MORC3 depletion with HFT-shNeg and 560 
HepaRG cells included as controls. Tubulin was included as a loading control. 561 
Characterization of MORC3 depleted HFT cells (B) and HepaRG cells (C). Mock HFT- and 562 
HA-shMORC3-1339 and control cells were immuno-stained for PML (red) and MORC3 563 
(green) (left panels), and Sp100 (green) and PML (red) (right panels) to confirm MORC3 564 
depletion and assess effects on PML NBs. DAPI staining of the nuclei is shown in blue in the 565 
merged panels. 566 
 567 
Fig. 6: Recruitment of PML NB proteins to viral DNA is diminished in the absence of 568 
MORC3. (A) HFT-shMORC3-1339 and -shNeg cells were infected with dl0Y4 (MOI 2) for 569 
24 h. Cells were immuno-stained using PML (5E10) (red), MORC3 (Novus biologicals) 570 
(blue) and nuclei stained with DAPI (far right panels) and visualized by confocal microscopy. 571 
Infected, or presumed infected cells surrounding a plaque were counted and divided into three 572 
categories which are represented here. Category 1: ICP4+/PML+ (foci of ICP4 and PML in 573 
close association at the nuclear periphery of a cell), Category 2: ICP4-/PML+ (foci of PML at 574 
the nuclear periphery of a cell in the pattern typical of an infected cell, but prior to detectable 575 
expression of ICP4), or Category 3: ICP4+/PML- (ICP4 foci only at the nuclear periphery of 576 
a cell). (B) Percentages of cells within each category are presented in bar graphs. Sp100, 577 
hDaxx and γH2AX were also assessed as described for PML with results represented as bar 578 
graphs. (C) HFT-shMORC3-1339 and -shNeg cells were infected with dl0Y4 (MOI 2) for 24 579 
h. Cells were immuno-stained using Sp100 (Sp26) (Red), PML (5E10) (blue) and nuclei were 580 
stained with DAPI (far right panels), while ICP4 was detected by the EYFP signal. 581 
 582 
Fig. 7: MORC3 has antiviral activity during ICP0-null mutant HSV-1 and wt HCMV.   583 
(A) Data from several independent viral plaque assays of both wt and ΔICP0 HSV-1 infected  584 
HFT- and HA- shMORC3-1335 and -1339 cells were averaged and normalized to the 585 
respective shNeg cell controls and plotted ± standard deviation. (B) Western blot analysis 586 
comparing infection efficiency of ΔICP0 HSV-1 within HFT-shMORC3-1339 and HFT-587 
shNeg cells over a time course infection. Cells were infected at MOI 2 with ΔICP0 HSV-1 588 
and lyzed at 2, 4, or 6 h p.i., and probed for ICP4, ICP0, UL42 and actin loading control. (C) 589 
HCMV viral plaque forming efficiencies using HFT-shMORC3-1335 and -1339 cells 590 
normalized to HFT-shNeg cells and plotted ± standard deviation. 591 
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